Applications Published 26 September 2001
Published: 16-Jun-2002
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).
Sustained release polymer-based water insoluble beads
Ben Gurion University of the Negev Research & Development Authority 1135021*Plastin promoted directed gene therapy
Yale University 1135022*Aminobenzisoxazole compounds and libraries thereof
Eli Lilly 1135023* Promoting biological effectiveness of exogenous chemical substances in plants
Monsanto 1135024* Plasmid maintenance system for antigen delivery
University of Maryland at Baltimore 1135025*Pharmacoemulsification apparatus with personal computer
Urich, Alex; Curtis, Michael; Pena, Greg; Martinez, Brent 1135054*Cleavable solid dosage forms and method for the production thereof
Knoll 1135092* Method for administering agents to the central nervous system
Chiron Corp 1135105*Sustained release matrix system for highly soluble drugs
Edward Mendell 1135106* Utilisation of capsules containing one or more antigenic substances for the prevention and treatment of autoimmune diseases
Bioserv 1135107*Method for producing agglomerates comprising a core-shell structure
BASF 1135108*Method for producing solid forms of administration by melt extrusion
BASF 1135109*Preparation of dry compsns soluble in the presence of water and avoiding maillard reaction in dry state and uses
Virbac 1135110*Autoadhesive oral transmucosal delivery dosage form
Controlled Therapeutics (Scotland) 1135111*An oral formulation for gastrointestinal drug delivery
Takada, Kanji 1135112*Treatment of Parkinson's disease with oligonucleotides
Thomas Jefferson University 1135113*Method for reducing free-radical induced injury
Rotta, Alexandre; Fuhrman, Bradley; Gunnersson, Bjorn; Steinhorn, David; Hernan, Lynn 1135114*Use of sibutramine for the treatment of disorders of the central nervous system
Mueller, Peter Sterling 1135115*Use of poly (hexamethylene) biguanidine for producing an agent for promoting the healing of uninfected wounds
Fresenius Kabi Deutschland 1135116*Method for treating chonic obstructive pulmonary disease
Abbott Laboratories 1135117*Dispersible compsns containing L-DOPA ethyl ester
Teva Pharmaceutical Industries 1135118*Glucose and lipid lowering compounds
Alteon 1135119*Stabilised injectable pharmaceutical compsns containing taxoid antineoplastic agents
Mylan Pharmaceuticals 1135120*Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
Eli Lilly 1135121*Use of amtolmetin guacyl as an antiinflammatory drug
Medosan 1135122*Use of isatin derivatives as ion channel activating agents
Neurosearch 1135123*Antihypertriglceridemic, antihyperglycaemic, antiangiogenic and wound healing substituted indolealkanoic acids
The Institutes for Pharmaceutical Discovery 1135124*Controlled-release dosage forms comprising zolpidem or a salt thereof
Sanofi-Synthelabo 1135125* MYT1 kinase inhibitors
SmithKline Beecham 1135126*New pharmaceutical compsn and the process for its preparation
Novo Nordisk 1135127*Novel method of treatment
SmithKline Beecham 1135128*Use of an N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical compsn for the treatment of indications related to angiogenesis
Novo Nordisk 1135129*Use of a prucalopride for the manufacture of a medicament for the teratment of dyspepsia
Janssen Pharmaceutica 1135130*Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
Berlex Laboratories 1135131*Inhibitors of multidrug transporters
Influx 1135132*Pentacyclic triterpenes
Micro Flo; Boehringer Ingelheim Pharmaceuticals 1135133*Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
Alcon Laboratories 1135134*CHK1 kinase inhibitors
SmithKline Beecham 1135135*Pharmaceutical compsns containing olanzapine-N-oxide
Speracor 1135136*Copolymer compsns for treating viral infections
Supratek Pharma 1135137*Use of 17-ketosteroids for the treatment of malaria and trypanosomiasis
Hollis-Eden Pharmaceuticals 1135138*Micronised eplerenone compsns
GD Searle 1135139*Use of ibandronate for promoting osseointegration of endoprostheses
Roche Diagnostics 1135140*Phosphilpase inhibitors for the treatment of cancer
Analytica 1135141*Production of a product enriched in isoflavone values from natural sources
Cognis 1135142*Immunomodulatory methods using carbohydrate antigens
President and Fellows of Harvard College 1135143*Compsns and methods for regulating bacterial pathogenesis
Princeton University 1135144*Isolated material having an antiorganotrophic effect
Endocrine Pharmaceuticals 1135145*Pharmaceutical compsn containing fish oil, vitamin E and C and acetylsalicyl acid against arteriosclerosis
Langhoff, Wolfgang; Laumann, Udo 1135146*Method for producing medicaments from pkant extracts, in a solid form of administration
Steigerwald Arzneimittelwerk 1135147*PGC-1, a novel brown far PPAR gamma coactivator
Dana-Farber Cancer Institute 1135149*Self-emulsifying compsns for drugs poorly soluble in water
Pharmasolutions 1135150*Peptoid and non-peptoid containing alpha-keto oxadiazoles as serine protease inhibitors
Cortech; Ono Pharmaceutical 1135151*A pharmaceutical compsns comprising cyclosporin in a lipid carrier
Lipocore Holding 1135152*Uses for EPH receptor antagonists, and agonists to treat vascular disorders
Genentech 1135153*Improvement of folliculogenesis
Akzo Nobel 1135154*Method of inhibiting ectopic calcification
University of Washington 1135155*Medicinal product and method for the treatment of conditions affecting neural stem cells or progentor cells
A+ Science Invest 1135156*Method for regulating the permeability of the blood-brain barrier
New York University 1135157*Enhanced vaccines
Resistentia Pharmaceuticals 1135158*Peptide-based vaccine for influenza
Yeda Research & Development Company 1135159*Chemotherapeutic compsn and method
Bioniche Life Sciences 1135161*Ordered molecular presentation of antigens, method of preparation and use
Cytos Biotechnology 1135162*Topical compsns comprising ascomycins
Novartis 1135163*Method for the treatment of inflammation
Bioniche Life Sciences 1135164*Stent having drug crystals thereon
Boston Scientific 1135165*Hapten-carrier conjugates for treating and preventing nicotine addiction
NABI 1135166*Methods and formulations for reducing circulating antibodies
La Jolla Pharmaceutical 1135167*Peptides carrying substances acorss the blood-brain barrier
Synt:em 1135168* Pharmaceutical compsns containing an anti-cancer agent and at least a peptide
Synt:em 1135169*Radioconjugation of internalising antibodies
Duke University 1135170*Agents provided for treating tumours, based on liposomes, and containing tamoxifen
Max-Delbruck-Centrum fur Molekulare Medizin 1135193*Process for the resolution of tramadol
Darwin Discovery 1135357*Derivatives of (+)-venlafaxine and methods of preparing and using the same
Sepracor 1135358*Novel 3-alkazoxybenzylamine derivatives and their uses as medicines for treating schizophrenia
Pierre Fabre Medicament 1135360*Therapeutic product and its use
Darwin Discovery 1135361*Process for the preparation of symmetrical diacylhydrzines
Great Lakes Chemical 1135363*4,3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction
American Home Products 1135365*3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compsns containing the same
Centaur Pharmaceuticals 1135367*
